Category: Clinical Trials

Exciting news is emerging from the world of metabolic health research: mazdutide, an investigational peptide-based therapy, has demonstrated significant reductions in both body weight and waist circumference in a major clinical trial. This dual-action benefit is particularly encouraging, as waist size is often used by researchers as an indicator of visceral fat and related metabolic health markers.

Mazdutide belongs to a class of peptide therapeutics designed to act on receptors involved in appetite regulation and energy metabolism, similar in concept to other GLP-1 based approaches that have reshaped the obesity treatment landscape in recent years. The latest trial results add mazdutide to a growing list of peptide candidates showing real promise for people seeking additional options in weight management support.

What makes this trial particularly noteworthy is the scale and rigor behind it. Large trials that track multiple metrics — not just weight on the scale, but also waist measurements — provide a fuller picture of how a therapy may influence overall body composition. Reductions in waist circumference alongside weight loss suggest that mazdutide may be helping address fat distribution patterns that are often linked to broader health considerations.

For the peptide research community, results like these are meaningful because they reinforce the potential of peptide-based approaches to play a expanding role in future metabolic therapies. As more data becomes available, researchers will likely continue to explore how mazdutide compares to existing options and whether it might offer unique advantages in terms of tolerability, dosing convenience, or magnitude of effect.

While mazdutide remains under clinical investigation and is not yet a widely available treatment, developments like this trial mark encouraging progress in the pipeline of peptide therapeutics aimed at supporting healthier body weight and metabolic outcomes. As always, we look forward to sharing further updates as more research unfolds. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Obesity drug mazdutide reduces weight and waist size in major trial – News-Medical

A new phase II/III clinical trial is underway to explore whether adding durvalumab, an immunotherapy monoclonal antibody, to standard chemotherapy before surgery can improve treatment outcomes for patients with high-grade upper urinary tract cancer. The study, registered on ClinicalTrials.gov, compares outcomes between patients receiving durvalumab plus chemotherapy and those receiving chemotherapy alone prior to surgical intervention.

Durvalumab works by helping the immune system recognize and attack cancer cells, potentially enhancing the body’s natural defenses against tumor growth. When paired with established chemotherapy drugs such as cisplatin, gemcitabine, and doxorubicin, researchers hope the combination may lead to greater tumor shrinkage before surgery compared to chemotherapy alone. This approach, known as neoadjuvant therapy, aims to make surgical removal of the cancer more effective by reducing tumor size beforehand.

Upper urinary tract cancers, which affect the renal pelvis and ureter, are relatively rare and can be challenging to treat effectively. Trials like this one represent an important step in expanding the range of therapeutic options available to patients, particularly by testing whether combining immunotherapy with traditional chemotherapy regimens offers additional benefit. The scientific rationale behind the combination is grounded in the complementary mechanisms of the two treatment types—chemotherapy directly targets rapidly dividing cancer cells, while immunotherapy works to boost the immune system’s own cancer-fighting capabilities.

This kind of research reflects the ongoing efforts within oncology to refine and personalize treatment approaches, potentially offering patients better outcomes and more effective paths toward remission. As the trial progresses, it will contribute valuable data to the broader understanding of how immunotherapy can be integrated into treatment protocols for less common cancers, potentially opening doors for future advances in care.

This article is for informational purposes only and is not intended as medical advice. Patients interested in clinical trials should consult with their healthcare provider.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

A newly registered clinical trial is set to evaluate glofitamab, an innovative immunotherapy, as a potential treatment for patients battling relapsed or refractory mantle cell lymphoma (MCL). This study, listed on ClinicalTrials.gov, will compare glofitamab used alone against two established treatment approaches chosen by physicians: a combination of rituximab and bendamustine, or a combination of lenalidomide and rituximab.

Mantle cell lymphoma is a rare and often aggressive form of non-Hodgkin lymphoma, and patients whose disease returns or resists initial treatment frequently face limited options. The launch of this trial reflects ongoing efforts within the research community to expand the toolkit available to oncologists and give patients renewed hope when earlier therapies have not achieved lasting results.

Glofitamab represents a class of therapies designed to help the body’s own immune system recognize and target cancer cells more effectively. By directly comparing this approach to well-established combination therapies, researchers aim to gather clear evidence about whether this newer option can offer meaningful benefits, whether in effectiveness, tolerability, or overall patient experience.

Studies like this one are an important part of how medicine advances—systematically testing new approaches against reliable standards of care ensures that any therapy which reaches wider use has been rigorously vetted. For patients and families affected by relapsed or refractory MCL, the initiation of this trial is an encouraging sign that new possibilities are actively being explored, and that the scientific community remains committed to improving outcomes for those with this diagnosis.

As with all clinical research, results will take time, and enrollment and study completion are the next milestones to watch. Patients interested in learning more about trial eligibility should consult with their healthcare providers. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator’s Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Researchers have launched a phase II clinical trial to evaluate a new treatment approach for nasopharyngeal carcinoma (NPC), a rare cancer that forms in the upper part of the throat behind the nose. The study is testing whether combining the immunotherapy drug nivolumab with established chemotherapy agents, gemcitabine and cisplatin, before radiation therapy can improve how well the body responds to treatment.

Nivolumab belongs to a class of therapies known as monoclonal antibodies, which work by helping the immune system recognize and attack cancer cells more effectively. When paired with chemotherapy drugs that target tumor growth through different mechanisms, researchers hope the combination may offer a more comprehensive attack on the cancer before patients undergo radiation.

One particularly encouraging aspect of this trial is its focus on children with NPC. The study aims to determine whether young patients might be able to receive reduced doses of radiation therapy while still achieving effective treatment outcomes. Since radiation therapy can carry long-term side effects, especially in developing bodies, finding ways to minimize exposure without sacrificing effectiveness would represent a meaningful advance in pediatric cancer care.

This kind of research reflects a broader trend in oncology: combining immunotherapy with traditional treatments to potentially boost effectiveness while working to reduce the burden of side effects on patients. By carefully studying both the benefits and any risks of adding nivolumab to the treatment regimen, researchers aim to build a clearer picture of how this combination performs in real-world patient populations.

Trials like this one are an important part of the broader effort to refine cancer treatment protocols, offering hope that future patients, including children, may benefit from therapies that are both effective and gentler on the body. As the trial progresses, its findings could help shape future treatment guidelines for this rare form of cancer.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

A newly launched clinical trial is set to take a closer look at how collagen peptide supplements may support people living with knee osteoarthritis, a condition that affects millions and often leads to persistent joint pain and reduced mobility. The study, registered on ClinicalTrials.gov and conducted at a hospital in Türkiye, will compare two different collagen formulations against a placebo to better understand their potential benefits.

Participants between the ages of 35 and 65 with diagnosed unilateral knee osteoarthritis will be randomly assigned to one of three groups: a hydrolyzed bovine collagen peptide group, a lower molecular weight bioactive collagen peptide group, or a placebo group. Over eight weeks, participants will take their assigned daily supplement, and researchers will track changes using a range of well-established questionnaires covering joint stiffness, physical function, quality of life, and detailed pain patterns.

What makes this study particularly interesting is its more nuanced approach to measuring pain. Rather than relying solely on standard pain scales, the research team plans to examine different pain patterns, including central sensitization, a phenomenon where the nervous system becomes more responsive to pain signals over time. This deeper look could help clarify not just whether collagen supplementation helps, but how and in what ways it might improve the day-to-day experience of people managing osteoarthritis.

Because the trial is double-blind, neither participants nor evaluators will know who received which supplement, helping ensure the results are as objective as possible. By comparing two distinct collagen formulations rather than just one product against placebo, the study could also offer useful insights into whether molecular weight or formulation differences influence outcomes.

While results are still to come, the launch of this trial reflects a growing scientific interest in better understanding how nutritional peptides might support joint health and quality of life for people with osteoarthritis. As the field continues to explore more comprehensive ways of measuring patient outcomes, studies like this one may help pave the way for more personalized, evidence-based approaches to joint care in the future.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Effects of Different Collagen Formulations on Knee Osteoarthritis

A promising new clinical trial initiative called ComboMATCH is now underway, offering a fresh approach to treating patients with locally advanced or advanced solid tumors. Rather than relying on a one-size-fits-all treatment plan, this screening trial uses genetic testing to identify specific mutations within a patient’s tumor, then works to match that patient with a targeted therapy combination designed to address those particular genetic changes.

The trial is specifically designed for patients whose cancer has progressed despite prior treatment, or for whom no standard therapy has been shown to extend survival — a population that often has limited options. By serving as a screening gateway to a broader network of coordinated clinical trials, ComboMATCH aims to streamline the process of connecting these patients with therapies that are more likely to be effective based on their tumor’s unique genetic profile.

This approach reflects the growing momentum behind precision oncology, a field built on the idea that understanding the genetic drivers of a tumor can lead to smarter, more personalized treatment decisions. Instead of guessing which therapy might work, doctors can use genetic data to guide their choices, potentially improving outcomes while also helping researchers learn more about which mutations respond best to which combination treatments.

What makes ComboMATCH especially encouraging is its scale and structure. By functioning as a centralized screening effort feeding into multiple downstream studies, it creates a more efficient pathway for matching patients to appropriate trials, reducing time and uncertainty for people who may have already tried multiple treatment approaches. This kind of coordinated infrastructure represents a meaningful step forward in how the research community organizes and delivers genetically-informed cancer care.

For patients and families navigating advanced solid tumors, initiatives like ComboMATCH offer a hopeful glimpse into the future of oncology — one where treatment decisions are increasingly guided by the specific biology of a person’s cancer rather than broad categories of disease. As this trial and its associated studies progress, they may help expand the range of options available to patients who need them most.

This article is for informational purposes only and is not intended as medical advice. Patients interested in clinical trials should speak with their healthcare provider.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial